David Nierengarten

David Nierengarten

Analyst-Equity en
Wedbush Securities, Inc.
.
Finance
Consumer Services
Health Technology

Perfil

Dr. David Nierengarten is a Senior Analyst at Wedbush Securities, Inc. Dr. David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy.
His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models.
In addition, Dr. David Nierengarten, Ph.D.
has results in predicting Dendreon's looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.
Dr. David Nierengarten, Ph.D.
received his B.S.
in Biochemistry from the University of Wisconsin-Madison, and Ph.D.
in Molecular and Cell Biology from the University of California at Berkeley.

Cargos activos de David Nierengarten

EmpresasCargoInicio
Analyst-Equity -

Antiguos cargos conocidos de David Nierengarten.

EmpresasCargoFin
Corporate Officer/Principal 30/11/2010
Analyst-Equity 30/06/2007
Corporate Officer/Principal 30/05/2007
Corporate Officer/Principal 31/12/2004
Ver el detalle de la experiencia de David Nierengarten.

Formación de David Nierengarten.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

100 +

Relaciones de 1er grado

7

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas7

Finance

Health Technology

Finance

Consumer Services

Consumer Services

Finance

Finance

  1. Bolsa de valores
  2. Insiders
  3. David Nierengarten